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Summary.-N-Dephenylation of N-phenyl-2-naphthylamine (PBNA) is strictly
limited in dogs, and a5 mg/kg dose gives0-10 ,ug ofurinary2-naphthylamine (BNA),
whichdoesnot appear toundergofurther metabolism. Neither2-naphthylhydroxyl-
amine (BNHA) nor2-amino-1-naphthylsulphate were detected in the urine oftreated
animals. Urinary output of BNA varies markedly between dogs, and at different
times in the same animal. The extent of PBNA N-dephenylation is unaltered by
chronic administration.
Calculations based on Druckrey and Kupfmuller's equation (1948) and present
data indicate that, for dogs to form BNA tumours through exposure to a relatively
high dose-level of PBNA, the period of daily dosing would occupy, or even exceed, the
normal life-span. The carcinogenic risk of PBNA to human subjects is discussed.
TRACES of 2-naphthylamine (BNA)
impurity in the technical grade of the N-
phenyl-2-naphthylamine (PBNA) anti-
oxidant did not account for the presence
ofsmall amounts ofBNA, which have been
found (Kummer and Tordoir, 1975) in the
urine of operatives who had been exposed
occupationally to this antioxidant. Con-
sequently, these authors concluded that
the urinary BNA had been formed in vivo
through an unsuspected N-dephenylation
reaction, and this possibility posed the
question of the oncogenicity of PBNA.
A better understanding of the scope
and implications ofthis biotransformation
is therefore desirable. In this connection,
the PBNA metabolic product, BNA, is one
ofthe few compounds which are known to
lead to cancer in man. Since dogs are
susceptible to tumour induction by BNA
(Hueper, Wiley and Wolfe, 1938; Bonser,
1943), whereas mice and rats are not, and
since the tumours to which it (or its meta-
bolites) gives rise in both man and dogs are
almost entirely confined to the urinary
tract, dogs are the animals of choice for a
further study of PBNA N-dephenylation.
The present paper describes the results
obtained and their possible interpretation.
MATERIALS AND METHODS
Chemicals.-Commercial PBNA and BNA
were supplied by Imperial Chemical Indus-
tries Limited, Organics Division, Blackley,
Manchester. Synthetic N-phenyl-2-[1,4,5,8-
14C]naphthylamine ([14C]PBNA) had a speci-
fic activity of 1 44 mCi/mM (Walker and
Hathway, 1976). 2-Naphthylhydroxylamine
(BNHA), prepared by the method of Will-
statter and Kubli (1908), was, in our experi-
ence, always contaminated with BNA. 2-
Amino-l-naphthyl sulphate was synthesized
by the method of Boyland, Manson and Sims
(1953).
Experiments in animals.-Adult hounds
(12 months old; 10-15 kg body wt.) were
used (beagles maintained as a closed colony).
During experiments, the animals were housed
singly in stainless-steel metabolism cages,
and were maintained on a standard pellet
(Kennel Kernel) diet, supplemented with
meat. After a period of acclimatization in
the metabolism cages, each dog swallowed a
gelatin capsule containing either 150 ,uCi of
[14C]PBNA or unlabelled PBNA at a dose
level of 5mg/kg. Dogs subjected to the
chronic dosing regimen were each admini-
stered a 400-mg dose of PBNA, 5 days/weekDEPHENYLATION OF PHENYL-NAPHTHYLAMINE IN DOGS
for 4 weeks. In both cases, unrestricted food
and waterweresuppliedthroughouttheperiod
of the experiment. Urine and faeces were
collected separately at daily intervals. The
urine was frozen immediately by a surround-
ing jacket of solid CU2, and was protected
from direct light. Urine and faeces were
stored at -20°.
Measurement of radioactivity. An auto-
mated and computerized Intertechnique
Model SL30 Liquid Scintillation Spectro-
meter was used for measurement of 14C, mak-
ing use of standard channels-ratio quench-
correction curves. Liquid samples were
mixed with standard scintillation, and radio-
assayed direct, and samples of faeces were
burnt in an Intertechniques " Oxymat ",
solid-sample oxidizer.
Gas chromatography.-Solutions were ana-
lysed for relevant compounds with a Pye
Model 104 instrument that was equipped with
electron-capture detection and glass columns,
wbich (5 ft long x4 mm internal diameter)
were packed with 20% (w/w) of OV-17
on 5 o Gas Chrom Q (60-80 mesh size).
A column temperature of 180°C was used.
All the columns were operated at a 100-ml/
min flow-rate of N2.
Mass spectrometry. Mass spectra were
obtained by using an LKB9000 gas chromato-
graphy (GC) mass spectrometer system, fitted
with the previously described glass column.
The column temperature was 210°C, and the
column was operated at a 30-ml/min flow-rate
of He. Multiple-ion-detection was used to
monitor the relevant ions.
Estimation of BRA in the urine.-All
operations were at 5-10°C, and in artificial
light, to minimize decomposition of BNA.
The 3-day urine, which was collected after
PBNA administration, was thawed, filtered
and shaken with ether (50 ml), and the
mixture was centrifuged (2 k rev/min; 10 min)
to break emulsions. Combined ether extracts
(4 x 50 ml) were extracted with 2N HCI
(3 x 10 ml), neutralized with 2N NaHCO3,
and back-extracted with ether (3 x 5 ml).
This ethereal solution was evaporated to low
bulk, dried with anhydrous MgSO4 and
treated with 0-01 ml of heptafluorobutyryl
chloride. After shakina for 5 min, the solu-
tion was mixed with 7 ml ofO-O1N borax, and
the resulting mixture was shaken for 16 h.
The ether layer was then removed, dried, and
made up to 2 ml with more dry ether. 1-5-,ul
samples were analysed by GC, using electron-
24
capture detection. The retention time of an
authentic sample of the heptafluorobutyryl
BNA derivative was 2-5 min, under our GC
conditions (vide supra).
A calibration curve of GC response vs
BNA in urine was constructed by adding 100,
200, 300 and 400 ng quantities of BNA to
500-ml volumes of urine and extracting (vide
supra). This standard curve corrected for
losses incurred through extraction and deriva-
tive formation.
Detection of BNHA in the urine.-Ether
extracts (vide supra, under the estimation of
BNA) of the 24-h urines of dogs dosed with
PBNA were dried with anhydrous MgSO4 and
evaporated to ca 0 5 ml. Aliquots were
analysed by GC mass spectrometry using the
sensitive multiple-ion detection facility.
Detection of2-amino-i-naphthyl sulphate in
the urine.-Urine, collected for 24 h after
dosing with PBNA, was freeze-dried, and the
residue was heated with acetic anhydride
(80 ml) and methane sulphonic acid (2 ml) at
100°C for 1 h (Paulson and Portnoy, 1970).
The reactionmixture was poured onto ice, left
for 16 h, and neutralized with 2N NaHCO3.
Ether extracts (3 x 25 ml) of the resulting
suspension were dried with anhydrous MgSO4,
and evaporated to ca 1 ml. Samples were
analysed for 2-acetamido-1-acetoxynaphthal-
ene by GC mass spectrometry, using multiple-
ion detection.
RESULTS
Preliminary experiments revealed that
when dogs were dosed intragastrically
with [14C]PBNA, > 90% of the radio-
activity was excreted from the body with-
in 3 days; the principal eliminative route
was biliary/faecal. Irr6spective of 4
weeks' chronicadministration oflargedaily
doses of unlabelled PBNA, the 3-day
urinary excretion of 14C from a single oral
administration of [14C]PBNA did not
exceed 2.8% of the dose (Table).
In contrast to Kurnmer and Tordoir's
(1975) work in human subjects who had
been exposed to PBNA, we were unable to
detect, by thin-layer chromatography,
BNA in the urine of treated (5 mg/kg)
dogs. Even when [14C]PENA of high
specific activity was used, and the deve-
loped plates were analysed by autoradio-
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graphy, it was impossible to identify [14C]-
BNA with certainty. However, unfortu-
nately Kummer and Tordoir (1975) do not
give details of their thin-layer chromato-
graphy procedure, and consequently in our
exploratory work we were uncertain
whether we were using essentially the
same method. Hence, it was advan-
tageous to employ the heptafluorobutyryl
derivative of BNA (personal communica-
tion from the Laboratory of the Govern-
ment Chemist) which was more stable than
the parent amine and eminently suited to
gas chromatography, and which was mea-
sured very accurately by electron capture.
Whilst the lower limits ofdetection for the
BNA heptafluorobutyryl derivative were
compatible with as little as 10 ng of aro-
matic amine in the urine, at least 50 ng
were necessary for reliable measure-
ment, because of the presence of other
compounds, producedbyderivativeforma-
TABLE.-Urinary Excretion* of Radio-
activity and of the BNA Metabolite in
Dogs Dosed Orally with [14C]-PBNA
before and after 3 weeks' Chronic Admini-
stration ofPBNA
The dogs Excretion Excretion
_-------~--------, of 140 of BNA
No. Sex (% of dose) (ng)
Single doses (5 mg/kg) of [14C]PBNA or
unlabelled PBNA
748
757
758
786
789
807
815
889
894
Y
y
rd
{!
2 -3
1 -4
2-8
2-1
_t
0-1
0-6
1-1
9600
1500
4100
115
40
0
85
<50
0
760
<50
670
Single doses (5 mg/kg) of [14C]PBNA or unlabelled
PBNA, after 4 weeks' chronic administration of
400 mg PBNA per animal, 5 days/week
786 ,3 - 256
789 - 189
807 , 09 7070
815 0O9 170
889 S - 90
894 9 1.1 2480
* 3-day excretions.
t Unlabelled PBNA, therefore no radioactivity
data.
tion, that respond to electron-capture
detection.
Experiments in dogs (Table) demon-
strate the strictly limited extent ofPBNA
N-dephenylation. Thus, dogs given a
5 mg/kg dose of PBNA excreted 0-10 jug
of BNA. A most conspicuous feature of
the results is the large variation in output
ofBNA between dogs and the large fluctu-
ations in output at different times in an
individual animal. The possibility that
occupational exposure to PBNA may
induce the drug-metabolizing enzymes and
cause increased PBNA N-dephenylation
was tested in the present work by the
chronic dosing ofdogs withPBNA. How-
ever, these animals, when subsequently
given PBNA (5 mg/kg), did not show a
consistently increased excretion of BNA
(Table), which would have been commen-
surate with drug-metabolizing enzyme
induction.
Numerous investigations (inter alia
Bonser et al., 1952; Radomski and Brill,
1971) indicate that BNA requires meta-
bolic activationbefore exerting its carcino-
genic effect, and in this BNHA is strongly
implicated as the carcinogenic metabolite.
Consequently, in the present work, the
presence in the urine of BNA per se is not
necessarily indicative of carcinogenic risk.
We have therefore investigated the urine
of PBNA-treated dogs for the products of
further metabolism of BNA, viz. BNHA
and 2-amino-1-naphthyl sulphate, the
major BNA metabolite (Deichmann and
Radomski, 1969). The multiple-ion de-
tection facility of the mass spectrometer
revealed neither the 2-amino-1-naphthvl
sulphate derivative, 2-acetamido-1-acet-
oxynaphthalene, in freeze-dried urine
that had been submitted to an acetylation
procedure, nor BNHA in an unprocessed
urinary solvent extract. In fact, the
lower limits of detection for the latter
substance did not fall below 50ng, because
of the presence of other complicating
naphthalene metabolites with very similar
retention times to that of BNHA; deriva-
tive formation did not improve the sensi-
tivity ofmultiple-ion detection for BNHA.
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However, the sensitivity of multiple-ion
detection ought to have been more than
adequate to measure the amounts of
BNHA which might have been formed.
It may be relevant that the low concentra-
tions of BNA formed from PBNA may be
metabolized more slowly than high con-
centrations resulting from dosing with
BNA per se, but since solutions of BNHA
are rather unstable, small amounts may
escape detection through decomposition.
DISCUSSION
In general, the present results in dogs
are similar to those (Kummer and Tordoir,
1975) in healthy human volunteers.
Kummer and Tordoir (1975) administered
an acute 10-mg dose of PBNA to human
subjects, who excreted 10-5 to 10-4 of the
dose as BNA; whereas in the present work,
dogs given a 5 mg/kg dose of PBNA (i.e.
75 mg for a 15-kg dog) excreted 10-6 to
5 X 10-5 of the dose as BNA. There is a
very considerable inter-subject variation
in the two experimental groups. While
the variation is greater in dogs than in the
human subjects, it is relevant that BNA
was measured satisfactorily in the urine of
only 7/19 human subjects, owing to the
insensitivity of the assay employed.
Two additional points deserve mention.
The first one concerns the possible
oncogenic implications in dogs of PBNA
N-dephenylation. While there are no
carcinogenicity data in dogs for PBNA,
BNA is a frank carcinogen in this species.
Carcinogenicity data for BNA in dogs
(Conzelman and Moulton, 1972) indicated
a dose-response relationship, and the dura-
tion ofexposure contributed apparently to
the tumourigenic process. The total dose
required to produce tumours with a small
daily dose over a long period of time was
considerably smaller than with a large
daily dose administered for a shorter
period. Conzelman and Moulton's obser-
vation (1972) agrees with the finding
(Radomski and Brill, 1971) that a 14-fold
reduction in chronic dose-level of BNA to
dogs resulted in only a 4-fold reduction in
the amount of suspected carcinogen,
BNHA, excreted in the urine. Conzelman
and Moulton (1972) applied Druckrey and
Kuipfmiiller's (1948) equation (dtn k,
where d is the daily dose, expressed in
mg/kg, t is the time elapsed between initi-
ation of treatment and tumour formation
(months), and n is a small positive integer),
which describes the dose-effect and time
relationship for animals subjected to daily
dosing with acarcinogen, totheirowndata,
and they found n -4. On the assump-
tion that this relationship applies to a
biological situation in which BNA is pro-
duced in vivo at a steady daily rate,
dependent upon chronic dosing with the
parent PBNA, then the time that would
have to elapse for tumours to be formed in
an " at risk " sub-population would be
approximately 19 years, ifthe daily intake
(10 fig) of BNA for a 15-kg dog corre-
sponded to the highest recorded level in
the Table. Such a calculation attempts to
take into account the considerable indivi-
dual variability which we have found, and
the possibility that certain individuals
might be more susceptible to tumour
induction. However, the corresponding
value would be approximately 31 years, if
1500 ng of BNA (the average amount for
all of the dogs in the Table) were taken as
the daily exposure. Thus, calculations
from the present data show that, for dogs
to form BNA tumours through exposure
to arelativelyhigh dose level ofPBNA, the
period of daily dosing would occupy, or
even exceed, the life-span of the species.
With regard to the situation in man,
Scott (1962) stated that no tumours had
been reported amongst operatives engaged
in the large-scale manufacture ofPBNA in
a number of countries over many years.
More recently, epidemiological studies
(Veys, 1973; Fox, Lindars and Owen,
1974) indicate that in operatives who have
been involved with widespread use of the
present technical grade PBNA, the inci-
dence of bladder tumours is no greater
than in the human population at large.
Ifit is permissible to make any correlation
between the PBNA-treated animals and
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PBNA-exposed man, particularly in his
working environment (Kummer and Tor-
doir, 1975) this suggests a quite unrealistic
period of exposure to PBNA for BNA
tumours to appear, although in the
present studies the dogs seem to have been
subjected to more than 10 times the dose
level ih terms of mg/kg body weight.
Hence, we suggest that the levels ofBNA
produced are so low that N-dephenylation
of PBNA in vivo does not give rise to
carcinogenic risk.
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